This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Biton, V. Articles by Hammer, A. E. Search for Related Content PubMed PubMed Citation Articles by Biton, V. Articles by Hammer, A. E. Social Bookmarking                   What's this?

Lamotrigine Versus Valproate Monotherapy—Associated Weight Change in Adolescents With Epilepsy: Results From a Post Hoc Analysis of a Randomized, Double-Blind Clinical Trial

Arkansas Epilepsy Program Little Rock, Arkansas

Paul Levisohn, MD

The Children's Hospital and the Departments of Pediatrics and Neurology University of Colorado Health Sciences Center Denver, Colorado

Sheri Hoyler, PharmD

GlaxoSmithKline Research Triangle Park, North Carolina Department of Pharmacotherapy, College of Pharmacy University of North Carolina Chapel Hill, North Carolina

Alain Vuong, BS

GlaxoSmithKline Research Triangle Park, North Carolina

Anne E. Hammer, BS

GlaxoSmithKline Research Triangle Park, North Carolina

Recent trends toward obesity and associated health risks in children highlight the significance of weight gain as a side effect with certain antiepilepsy drugs. No previous study has prospectively compared, in adolescents, weight effects for two commonly used antiepilepsy drugs. We report results from a post hoc subanalysis of adolescent data from a randomized, double-blind study comparing weight effects of lamotrigine and valproate. Patients were

12 years of age with new-onset partial or generalized seizures who were randomized 1:1 to lamotrigine or valproate. Patients were escalated to a dose range of 100 to 500 mg/day for lamotrigine and 10 to 60 mg/kg/day for valproate based on clinical response, with target doses maintained for 24 weeks. Results are reported for adolescents aged 12 to 20 years. Weight changes during maintenance were higher (P < .05) in valproate (n= 20) patients than in lamotrigine ( n= 18) patients, and change in body mass index was higher (P < .05) in valproate patients at the end of the study. At week 32, mean body mass index in the valproate group was above the 85th percentile representing "at risk for overweight." Whereas weight remained stable in adolescents treated with lamotrigine, weight increased in those treated with valproate by week 10 of this study and continued to increase at the end of the study. (J Child Neurol 2003; 18: 133—139).

Journal of Child Neurology, Vol. 18, No. 2, 133-139 (2003)
DOI: 10.1177/08830738030180021701


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Sharpe, T. Wolfson, and D. A. Trauner Weight Gain in Children Treated With Valproate J Child Neurol, March 1, 2009; 24(3): 338 - 341. [Abstract] [PDF]

				S. Grosso, R. Mostardini, B. Piccini, and P. Balestri Body Mass Index and Serum Lipid Changes During Treatment with Valproic Acid in Children with Epilepsy Ann. Pharmacother., January 1, 2009; 43(1): 45 - 50. [Abstract] [Full Text] [PDF]

				R. D. Sheth and B. E. Gidal Topical Review: Optimizing Epilepsy Management in Teenagers J Child Neurol, April 1, 2006; 21(4): 273 - 279. [Abstract] [PDF]

				D. C. Lagace, R. S. McLeod, and M. W. Nachtigal Valproic Acid Inhibits Leptin Secretion and Reduces Leptin Messenger Ribonucleic Acid Levels in Adipocytes Endocrinology, December 1, 2004; 145(12): 5493 - 5503. [Abstract] [Full Text] [PDF]

				R. Sankar Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues Neurology, November 23, 2004; 63(10_suppl_4): S30 - S39. [Abstract] [Full Text]